...
首页> 外文期刊>American Journal of Physiology >Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension.
【24h】

Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension.

机译:磷酸二酯酶1的抑制作用增强了急性肺动脉高压清醒羔羊对吸入一氧化氮的肺血管舒张反应。

获取原文
获取原文并翻译 | 示例

摘要

Phosphodiesterase 1 (PDE1) modulates vascular tone and the development of tolerance to nitric oxide (NO)-releasing drugs in the systemic circulation. Any role of PDE1 in the pulmonary circulation remains largely uncertain. We measured the expression of genes encoding PDE1 isozymes in the pulmonary vasculature and examined whether or not selective inhibition of PDE1 by vinpocetine attenuates pulmonary hypertension and augments the pulmonary vasodilator response to inhaled NO in lambs. Using RT-PCR, we detected PDE1A, PDE1B, and PDE1C mRNAs in pulmonary arteries and veins isolated from healthy lambs. In 13 lambs, the thromboxane A(2) analog U-46619 was infused intravenously to increase mean pulmonary arterial pressure to 35 mmHg. Four animals received an intravenous infusion of vinpocetine at incremental doses of 0.3, 1, and 3 mg.kg(-1).h(-1). In nine lambs, inhaled NO was administered in a random order at 2, 5, 10, and 20 ppm before and after an intravenous infusion of 1 mg.kg(-1).h(-1) vinpocetine. Administration of vinpocetine did not alter pulmonary and systemic hemodynamics or transpulmonary cGMP or cAMP release. Inhaled NO selectively reduced mean pulmonary arterial pressure, pulmonary capillary pressure, and pulmonary vascular resistance index, while increasing transpulmonary cGMP release. The addition of vinpocetine enhanced pulmonary vasodilation and transpulmonary cGMP release induced by NO breathing without causing systemic vasodilation but did not prolong the duration of pulmonary vasodilation after NO inhalation was discontinued. Our findings demonstrate that selective inhibition of PDE1 augments the therapeutic efficacy of inhaled NO in an ovine model of acute chemically induced pulmonary hypertension.
机译:磷酸二酯酶1(PDE1)在全身循环中调节血管张力和对释放一氧化氮(NO)药物的耐受性。 PDE1在肺循环中的任何作用仍然不确定。我们测量了肺血管中编码PDE1同工酶的基因的表达,并检查了长春西汀对PDE1的选择性抑制是否减轻了肺动脉高压并增强了对羔羊吸入NO的肺血管舒张反应。使用RT-PCR,我们从健康羔羊中分离出了肺动脉和静脉中的PDE1A,PDE1B和PDE1C mRNA。在13只羔羊中,血栓烷A(2)类似物U-46619静脉内输注以将平均肺动脉压增加至35 mmHg。四只动物以0.3、1和3 mg.kg(-1).h(-1)的增量剂量接受了长春西汀的静脉内输注。在九只羔羊中,在静脉输注1 mg.kg(-1).h(-1)长春西汀之前和之后,以2、5、10和20 ppm的随机顺序吸入NO。长春西汀的给药不会改变肺和全身的血流动力学或经肺的cGMP或cAMP释放。吸入NO选择性降低平均肺动脉压,肺毛细血管压力和肺血管阻力指数,同时增加经肺cGMP的释放。 NO吸入后,长春西汀的添加可增强NO呼吸诱导的肺血管舒张和经肺cGMP释放,而不会引起全身性血管舒张,但不会延长NO吸入后的肺血管舒张持续时间。我们的发现表明,在急性化学诱导的肺动脉高压的绵羊模型中,选择性抑制PDE1可增强吸入NO的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号